TY - JOUR T1 - Is ATP7B a Predictive Marker in Patients With Ovarian Carcinoma Treated With Platinum-Taxane Combination Chemotherapy? JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 60 LP - 64 DO - 10.1097/IGC.0b013e318275afef VL - 23 IS - 1 AU - Hiroshi Katagiri AU - Kentaro Nakayama AU - Mohammed Tanjimur Rahman AU - Munmun Rahman AU - Atsuko Katagiri AU - Tomoka Ishibashi AU - Masako Ishikawa AU - Kouji Iida AU - Satoru Nakayama AU - Yoshiro Otsuki AU - Kohji Miyazaki Y1 - 2013/01/01 UR - http://ijgc.bmj.com/content/23/1/60.abstract N2 - Objective This study examined the prognostic significance of copper-transporting P-type adenosine triphosphatase (ATP7B) expression in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy.Methods Expression of ATP7B in ovarian carcinoma was assessed by immunohistochemistry and clinical data collected by retrospective review of medical charts.Results Overexpression of ATP7B was identified in 25 (29.1%) of 86 ovarian carcinomas. The frequency of ATP7B expression in clear cell carcinomas was significantly higher than that in serous high-grade carcinomas (P < 0.05). We observed no statistically significant correlations between high ATP7B protein expression and either disease-free survival (P = 0.722) or overall survival (P = 0.389).Conclusions Our study is the first to demonstrate a lack of statistically significant differences between ATP7B positive and negative cases with respect to prognosis of patients with ovarian carcinoma treated with a platinum-taxane combination regimen. However, that ATP7B expression in clear cell carcinomas was significantly higher than that in serous carcinomas may partially explain the difference in chemotherapeutic response and prognosis between patients with these 2 types of carcinomas. ER -